Department of Thoracic Surgery, Nippon Medical School Hospital, Tokyo, Japan.
Department of Cell Pathology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
Thorac Cancer. 2024 Jun;15(18):1429-1436. doi: 10.1111/1759-7714.15325. Epub 2024 May 13.
BACKGROUND: Photodynamic therapy (PDT) is an antitumor therapy and has traditionally been regarded as a localized therapy in itself. However, recent reports have shown that it not only exerts a direct cytotoxic effect on cancer cells but also enhances body's tumor immunity. We hypothesized that the immunological response induced by PDT could potentially enhance the efficacy of programmed death-1 (PD-1) / programmed death-ligand 1 (PD-L1) blockade. METHODS: The cytotoxic effects of PDT on colon 26 cells were investigated in vitro using the WST assay. We investigated whether the antitumor effect of anti-PD-1 antibodies could be amplified by the addition of PDT. We performed combination therapy by randomly allocating tumor-bearing mice to four treatment groups: control, anti-PD-1 antibodies, PDT, and a combination of anti-PD-1 antibodies and PDT. To analyze the tumor microenvironment after treatment, the tumors were resected and pathologically evaluated. RESULTS: The viability rate of colon 26 cells decreased proportionally with the laser dose. In vivo experiments for combined PDT and anti-PD-1 antibody treatment, combination therapy showed an enhanced antitumor effect compared with the control. Immunohistochemical findings of the tumor microenvironment 10 days after PDT indicated that the number of CD8+ cells, the area of Iba-1+ cells and the area expressing PD-L1 were significantly higher in tumors treated with combination therapy than in tumors treated with anti-PD-1 antibody alone, PDT alone, or the control. CONCLUSIONS: PDT increased immune cell infiltration into the tumor microenvironment. The immunological response induced by PDT may enhance the efficacy of PD-1/PD-L1 blockade.
背景:光动力疗法(PDT)是一种抗肿瘤疗法,传统上被认为是一种局部治疗方法。然而,最近的报告表明,它不仅对癌细胞具有直接的细胞毒性作用,而且还增强了机体的肿瘤免疫。我们假设 PDT 诱导的免疫反应可能增强程序性死亡受体 1(PD-1)/程序性死亡配体 1(PD-L1)阻断的疗效。
方法:通过 WST 测定法在体外研究 PDT 对结肠 26 细胞的细胞毒性作用。我们研究了添加 PDT 是否可以增强抗 PD-1 抗体的抗肿瘤作用。我们通过将荷瘤小鼠随机分配到四个治疗组:对照组、抗 PD-1 抗体组、PDT 组和抗 PD-1 抗体和 PDT 的联合治疗组,来进行联合治疗。为了分析治疗后的肿瘤微环境,切除肿瘤并进行病理评估。
结果:结肠 26 细胞的存活率与激光剂量成比例下降。在联合 PDT 和抗 PD-1 抗体治疗的体内实验中,与对照组相比,联合治疗显示出增强的抗肿瘤作用。PDT 后 10 天肿瘤微环境的免疫组织化学发现,与单独使用抗 PD-1 抗体、PDT 或对照组相比,联合治疗组肿瘤中 CD8+细胞的数量、Iba-1+细胞的面积和表达 PD-L1 的面积显著增加。
结论:PDT 增加了肿瘤微环境中免疫细胞的浸润。PDT 诱导的免疫反应可能增强 PD-1/PD-L1 阻断的疗效。
Acta Pharmacol Sin. 2025-2
Cochrane Database Syst Rev. 2018-2-6
Cancer Immunol Immunother. 2025-6-30
Cochrane Database Syst Rev. 2025-6-16
J Immunother Cancer. 2025-6-30